11æ17 ãã«ã½ã ã©ã¨ããæ°ããç¡ç å¤ãçºå£²ããã ã«ãã´ãª:ç¡ç é害ãªã¬ãã·ã³ 2014å¹´9æ26æ¥ã«å ¨ãæ°ããã¿ã¤ãã®ç¡ç å¤ã§ãããã«ã½ã ã© Belsomraï¼ä¸è¬åã¹ãã¬ããµã³ããSuvorexantï¼ã¨ããè¬ãæ¥æ¬ã§ãæ¿èªããããå½å ã§ã¯11æä¸æ¬ãã使ç¨ã§ããã®ã§ã¯ãªããããã ï¼MSDã®HPããããã«ã½ã ã©æ¿èªã®ãç¥ããï¼http://www.msd.co.jp/newsroom/msd-archive/2014/pages/product_news_0926_2.aspxï¼ãã«ã½ã ã©ã®æ²»é¨ã«ã¤ãã¦ãæ²»é¨çªå· NCT01097616ï¼ãhttp://clinicaltrials.gov/show/NCT01097616 ãã«ã½ã ã©ã¯ä¸çåã®ãªã¬ãã·ã³å容ä½ï¼ã»ï¼ï¼OX1RãOX2Rï¼ãåæã«é»å®³ããç¡ç å¤ã§ããï¼dual orexin receptor antagonist

{{#tags}}- {{label}}
{{/tags}}